Trial Profile
Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Temsirolimus (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Anal cancer; Breast cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Periampullary cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thymoma; Thyroid cancer
- Focus Adverse reactions
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 19 Dec 2013 Planned end date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 11 Jun 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.